Answers are grounded in this paper and cite their sources.
Significance Antibiotics generally target one of five essential cellular functions in bacteria, but many of these targets are now compromised through rapidly spreading antibiotic resistance. Bedaquiline (BDQ), a new FDA-approved antitubercular drug, targets energy metabolism: defining cellular energetics as a new target space for antibiotics. This is a relatively unexplored area, as BDQ was only FDA approved in 2012. Several studies have recently found that BDQ stimulates mycobacterial respiration, in addition to inhibiting its molecular target, the F 1 F o -ATP synthase. We show that BDQ is an ionophore, which shuttles H + and K + ions across membranes, and propose that this activity may contribute to killing of mycobacteria by BDQ. Combining ionophoric activity with high-affinity membrane protein inhibition may enhance the specificity and potency of antibiotics.
No takes yet. Share an insight, caveat, or question.
Hards et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: